Codiak Biosciences Lines up for $86 Million IPO

Codiak BioSciences is aiming for a $86 million initial public offering.

The Cambridge, Mass.-based company, which launched in 2015, filed a prospectus for its IPO with the U.S. Securities and Exchange Commission this week. The company is banking on investors approving of its approach to harness exosomes, which had once been considered the cells’ garbage cans whose job was to carry unnecessary cellular materials out of the cell, as a means of pioneering a new class of biologic medicines.